Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients
Coagulation activation frequently occurs in cancer patients, resulting in thromboembolic complications and/or intravascular coagulation activation. The mechanisms leading to these alterations still are poorly understood. One explanation for the coagulation activation in malignant diseases is the presence of a direct factor X-activating cancer procoagulant.
Coagulation activation in lung cancer patients develops at earlier stages than factor X activation; we demonstrated increased factor IXiAT complexes in addition to elevated TAT complexes. The increases of factor IXiAT complexes were not dependent upon the stage of the disease. In contrast, TAT complexes were higher in patients suffering from advanced pulmonary non-small cell carcinoma than in patients with limited disease. In conclusion, coagulation activation in pulmonary cancer patients occurs at earlier steps in the coagulation cascade than factor X activation. While this activation is not dependent upon the stage of the disease, the observation that TAT complexes showed higher elevations in patients with advanced than in those with limited pulmonary nonsmall cell carcinoma could be an indication of a cancer procoagulant that directly activates factor X.
Key wordsFactor IXiAT complex TAT complex Protein C Coagulation activation Lung cancer
Unable to display preview. Download preview PDF.
- 1.Ambrus JL, Ambrus CM, Mink IB, Pickren JW (1975) Causes of death in cancer patients. J Med: 61–64Google Scholar
- 3.Bleyl H, Róka L (1990) Nachweis von Umsatzprodukten aktivierter Gerinnungsfaktoren. Med Welt 41: 927–932Google Scholar
- 6.Dvorak HF (1987) Thrombosis and cancer. Human Pathol 18: 275–284Google Scholar
- 8.Edwards RL, Rickles FR, Moritz ThE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O'Donnell JF, Headley E, Kim S-H, O'Dell R, Tornyos K, Kwaan HC (1987) Abnormalities of blood coagulation tests in patients with cancer. J Clin Pathol 88: 596–602Google Scholar
- 17.Hagedorn AB, Bowie EJW, Elveback LR, Owen CA (1974) Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 49: 649–653Google Scholar
- 26.Rickles FR, Hancock WW, Edwards RL, Zacharski LR (1988) Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemost 14: 88–94Google Scholar
- 29.Sproulw EE (1983) Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 34: 566–585Google Scholar
- 31.Tatra G, Reinthaller A (1991) Elevated thrombin-antithrombin III complex concentrations in patients with gynaecological malignancy. Klin Wochenschr 69: 124–127Google Scholar